Integra LifeSciences Reports Q4 Results and 2025 Outlook

Integra LifeSciences releases Q4 results exceeding expectations. Adjusted EPS of $0.97 reflects positive growth, but guidance falls short of analysts' estimates.

Date: 25-02-2025

AI Rating: 6

**Earnings Per Share (EPS)**: For the fourth quarter, adjusted earnings were reported at $0.97 per share, a notable increase from $0.89 per share in the previous year's quarter, which would give this a rating of 7 for being slightly positive. However, the first quarter guidance of $0.40 to $0.45 significantly trails the analysts' expectation of $0.56 per share, suggesting a rating of 5 for being slightly negative compared to expectations. For full-year 2025, the projected adjusted EPS of $2.41 to $2.51 aligns closely with the analysts’ expectation of $2.51 per share, indicating a neutral perspective with a rating of 6. **Revenue Growth**: Total revenues for Q4 were $442.65 million, surpassing last year's $397.04 million, reflecting a solid growth of 11.5%. With organic revenue growth at 3.5%, this underlines a positive performance, resulting in a rating of 7. Looking ahead, the first quarter revenue guidance of $375 million to $385 million falls below analysts' expectations of $411.71 million, adding a slight negative bias with a rating of 5. The full-year guidance of $1.650 billion to $1.715 billion is also similar to analysts' estimates of $1.71 billion, suggesting neutrality with a rating of 6.

Stocks: IART